News for Healthier Living

AACR: First-in-Class Covalent Werner Helicase Inhibitor Shows Clinical Proof-of-Concept in Phase I Trial

* RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors * Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors * This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies * Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development

April 27, 2025


May 9 2025

May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025

April 30 2025

April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025